# GCC Monoclonal Antibody Custom Service Market > GCC Monoclonal Antibody Custom Service Market Research Report By Type (Rat Custom Monoclonal Antibody, Rabbit Custom Monoclonal Antibody), By Application (Diagnostic Application (Biochemical Analysis (Pregnancy Cancer Hormonal Disorder And Infectious Diseases), Diagnostic Imaging (Cardiovascular Diseases, Cancer and Bacterial Infections), Therapeutic Application (MAb as Therapeutic Agents and MAb as Targeting Agents), Protein Purification) and By End User (Hospitals, Research) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.14% - **2024:** $ 20.5 Million - **2025:** $ 21.55 Million - **2035:** $ 35.58 Million - **Key Players:** Thermo Fisher Scientific (US), Roche (CH), AbbVie (US), Merck KGaA (DE), Amgen (US), Sartorius (DE), GenScript (CN), Lonza (CH), Boehringer Ingelheim (DE) **Report ID:** MRFR/HC/51230-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-monoclonal-antibody-custom-service-market-52991 --- ## Market Summary ## **GCC Monoclonal Antibody Custom Service Market Overview** As per MRFR analysis, the GCC Monoclonal Antibody Custom Service Market Size was estimated at 18.5 (USD Million) in 2023.The GCC Monoclonal Antibody Custom Service Market Industry is expected to grow from 19.5(USD Million) in 2024 to 47.1 (USD Million) by 2035. The GCC Monoclonal Antibody Custom Service Market CAGR (growth rate) is expected to be around 8.347% during the forecast period (2025 - 2035). ### **Key GCC Monoclonal Antibody Custom Service Market Trends Highlighted** The GCC Monoclonal Antibody Custom Service Market is expanding due to several stimulating factors. Healthcare advancements seek to offer more effective treatment options because of the growing chronic disease burden which includes cancer, diabetes, autoimmune, and other disorders, thus driving the demand for monoclonal antibodies. In addition to these factors, government policies in the GCC region aimed at improving the healthcare system and spending in biotechnological fields have bolstered the growth of custom antibody services. Exemplar, the UAE Vision 2021 focuses on healthcare innovation as a pillar of the strategy which is very beneficial for these markets. The GCC Monoclonal Antibody Custom Service Market still has plenty of unmet opportunities. The growing shift towards personalized medicine has many institutions and researchers adopting monoclonal therapy tailored to fit individual specific patient requirements. There is collaboration between local biotech firms and global research entities to create better therapeutic solutions which may serve custom service providers as a potential opportunity for broader service expansion. Increasing support on regulatory guidance and other enablement like approvals from the FDA Saudi Arabia is making the market more inviting for local and international stakeholders. Recently, there appears to be an increase in collaborations between research institutes and pharmaceutical companies across the GCC. Their primary focus is on the development and enhancement of monoclonal antibodies based on the increasing therapeutic needs. Meanwhile, technology and the market focus on more effective methods of antibody production is also changing. As academic institutions boost their studies on monoclonal antibodies, this will add to the innovation gap in the region and subsequently increase competition among providers in the area. ## **GCC Monoclonal Antibody Custom Service Market Drivers** ### **Growing Incidence of Chronic Diseases in the GCC Region** The increasing incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders in the Gulf Cooperation Council (GCC) region is a significant driver for the GCC Monoclonal Antibody Custom Service Market Industry. According to the World Health Organization, the Middle East has witnessed about a 12% increase in cancer cases over the last five years, with the Gulf States reporting high rates of breast and prostate cancers. Organizations such as the Qatar Cancer Society have highlighted the rising need for targeted therapies, which monoclonal antibodies provide. The heightened burden of chronic diseases creates an increasing demand for customized monoclonal antibody services that can specifically address unique patient profiles, driving market growth in the GCC area. Furthermore, policy changes in GCC countries focus on bolstering Healthcare systems to provide advanced treatment options, showcasing a market need that is likely to continue expanding in the coming years. ### **Rise in Research and Development Activities** The surge in Research and Development (R&D) activities within the GCC pharmaceutical sector is a crucial growth driver for the GCC Monoclonal Antibody Custom Service Market Industry. Governments across the GCC are increasingly investing in biotechnology and pharmaceutical research, fostering an ecosystem that encourages innovation. For instance, the Saudi Arabian government has initiated various funding programs to support biotech startups focusing on therapeutic developments, which is essential for utilizing monoclonal antibodies in treatments.This R&D concentration is further reflected in the establishment of institutions such as the King Abdullah International Medical Research Center, which actively integrates custom antibody services into their research agendas. This ecosystem is likely to generate a demand for custom monoclonal antibody services, making R&D a primary market driver in the GCC region. ### **Expansion of Healthcare Infrastructure** The expansion of healthcare infrastructure in the GCC region significantly contributes to enhancing the GCC Monoclonal Antibody Custom Service Market Industry. Governments in countries like the United Arab Emirates and Saudi Arabia are allocating substantial portions of their budgets to modernize healthcare facilities, building new hospitals, and upgrading diagnostic centers that offer advanced services like monoclonal antibody administration. The World Bank reported substantial investments, estimating that USD 38 billion is projected for healthcare infrastructure by 2025 across the GCC.This strengthening healthcare ecosystem enables better access and availability of monoclonal antibody services, promoting therapy options and spurring growth in the market. A more robust healthcare system facilitates collaborations among research institutions, clinics, and pharmaceutical companies, thus expanding the reach of custom monoclonal antibody services. ## **GCC Monoclonal Antibody Custom Service Market Segment Insights** ### **Monoclonal Antibody Custom Service Market Type Insights** The GCC Monoclonal Antibody Custom Service Market is significantly shaped by its Type segment, which includes diverse offerings such as Rat Custom Monoclonal Antibody and Rabbit Custom Monoclonal Antibody. The importance of these specific types comes from their extensive use in various fields including research, diagnostics, and therapeutics. Rat Custom Monoclonal Antibodies are particularly favored for their ability to produce high-affinity antibodies and are often employed in animal studies due to their physiological similarities to human systems. Additionally, Rabbit Custom Monoclonal Antibodies have been recognized for generating larger and more diverse antibodies compared to those from other species, making them highly useful in applications requiring intricate immune responses. As the GCC region continues to invest heavily in biomedical research and advanced healthcare technologies, the demand for these types of custom antibodies is on the rise. Market trends indicate that the increasing emphasis on personalized medicine, along with substantial government support for biopharmaceutical innovations, will likely amplify the usage of these antibodies across GCC nations. The GCC's strategic initiatives to strengthen its biotechnology infrastructure directly bolster the relevance of Rat and Rabbit Custom Monoclonal Antibodies, positioning them as significant components of the overall market landscape. As the GCC Monoclonal Antibody Custom Service Market evolves, the prevalence of these antibody types is expected to reflect not just their scientific utility but also their critical role in contributing to healthcare advancements and therapeutic breakthroughs within the region. ### **Monoclonal Antibody Custom Service Market Application Insights** The Application segment of the GCC Monoclonal Antibody Custom Service Market plays a crucial role in advancing healthcare solutions across the region. A significant portion of this segment is dedicated to Diagnostic Application, where monoclonal antibodies are pivotal for biochemical analysis, addressing conditions such as pregnancy, cancer, hormonal disorders, and infectious diseases. This is particularly important in the GCC, where the prevalence of chronic ailments necessitates robust diagnostic tools. In the realm of Diagnostic Imaging, monoclonal antibodies aid in identifying cardiovascular diseases, cancer, and bacterial infections, elevating precision in medical imaging and enhancing patient outcomes. Moreover, Therapeutic Application, wherein monoclonal antibodies serve as therapeutic and targeting agents, reflects the trend towards personalized medicine, an approach increasingly embraced in healthcare systems within the GCC. This personalized approach is expected to drive market growth, addressing diverse health challenges. Additionally, Protein Purification remains essential for ensuring high-quality production of monoclonal antibodies for therapeutic and diagnostic uses. The combination of these applications in the GCC region underscores the growing reliance on monoclonal antibodies as indispensable tools in modern medical practices. ### **Monoclonal Antibody Custom Service Market End User Insights** The End User segment of the GCC Monoclonal Antibody Custom Service Market plays a pivotal role in driving the overall market dynamics. This segment primarily encompasses Hospitals and Research sectors, which are vital for enhancing the capabilities of therapeutic solutions and diagnostics. Hospitals are increasingly adopting custom monoclonal antibodies due to their efficacy in personalized medicine, which encompasses cancer treatments and immunotherapy applications. Meanwhile, the Research sector is significantly focused on the development of novel therapeutic approaches, leveraging custom antibody services to explore and validate various biological pathways. This sector not only aims to unlock new possibilities in biotechnology and pharmaceuticals but also fosters collaborations with academic institutions for advancing innovative research. As a part of the GCC, the increased government investments in healthcare infrastructure and research initiatives, along with growing healthcare expenditure, provide essential support to both Hospitals and the Research sector. This collaboration is expected to foster advancements in treatment protocols and enhance research efficacy, ultimately benefiting patient outcomes and contributing to the expansion of the GCC Monoclonal Antibody Custom Service Market.The increasing emphasis on precision medicine and the growing prevalence of chronic diseases further accentuate the importance of specialized antibody services in the region. ## **GCC Monoclonal Antibody Custom Service Market Key Players and Competitive Insights** The GCC Monoclonal Antibody Custom Service Market has seen significant growth, driven by the increasing demand for tailored therapeutic solutions and advancements in biotechnology. With a burgeoning interest in personalized medicine and the rising prevalence of chronic diseases in the region, several key players have begun to establish or expand their services. The competition is characterized by a blend of established pharmaceutical companies and emerging biotech firms, all vying for a greater share of this dynamic market. The strategic focus lies in enhancing the efficiency and effectiveness of monoclonal antibody production processes, as well as in offering bespoke services that cater to the specific needs of clients looking for targeted therapies. This landscape is further fueled by partnerships, collaborations, and investments aimed at improving research and development capabilities, as well as regulatory compliance to meet the evolving healthcare requirements in the GCC.Siemens Healthineers has made notable advancements within the GCC Monoclonal Antibody Custom Service Market. Renowned for its cutting-edge healthcare technologies and diagnostic solutions, Siemens Healthineers leverages its expansive experience to provide high-quality monoclonal antibody services tailored to the region's needs. The company's strengths in innovation and reliable performance have allowed it to forge partnerships with various research institutions and healthcare providers, thereby increasing its influence and market penetration in the GCC. Siemens Healthineers also benefits from a robust portfolio that incorporates advanced imaging and laboratory diagnostics, which are integral to complementing its monoclonal antibody services. The firm's commitment to improving patient outcomes through precision medicine initiatives further solidifies its competitive position in this specialized market.Amgen, a key player in the GCC Monoclonal Antibody Custom Service Market, is recognized for its pioneering role in biotechnology and its extensive range of therapeutic products. The company offers an array of monoclonal antibodies utilized in various treatment protocols, including oncology and inflammatory conditions, enhancing its reputation in the GCC region. With a strong market presence, Amgen capitalizes on its robust research and development framework to innovate and expand its offerings through mergers and acquisitions, thus ensuring a wide spectrum of services and product availability. The company’s strategic collaborations with local healthcare institutions enable it to tailor its services to the specific demands of the GCC market, ensuring alignment with regional healthcare standards and needs. The strengths of Amgen lie not only in its comprehensive product range but also in its commitment to continuous improvement and investment in cutting-edge technology, which reinforces its competitive edge in a rapidly evolving landscape. ### **Key Companies in the GCC Monoclonal Antibody Custom Service Market Include** - Siemens Healthineers - [**Amgen**](https://www.amgen.com/about/therapy-areas/oncology/monoclonal-antibodies) - BristolMyers Squibb - Pfizer - Merck - Regeneron Pharmaceuticals - Roche - Johnson & Johnson - GSK - Thermo Fisher Scientific - Eli Lilly - Lonza - AbbVie - Sanofi - Novartis ## **GCC Monoclonal Antibody Custom Service Market Industry Developments** The GCC Monoclonal Antibody Custom Service Market has seen significant developments, particularly with major companies like Siemens Healthineers, Amgen, Bristol-Myers Squibb, Pfizer, Merck, and Regeneron Pharmaceuticals actively expanding their footprints in the region. In August 2023, Roche entered into a strategic partnership with a local biotech firm to enhance the development of monoclonal antibody therapies, responding to the growing demand for customized solutions. In December 2022, Johnson and Johnson expanded their facilities in the GCC to facilitate better production and research capabilities aimed at monoclonal antibody innovation. Significant increases in market valuation have been noted across the sector, with Thermo Fisher Scientific and Eli Lilly reporting growth attributed to enhanced investments in Research and Development and local collaborations. The last couple of years has seen a surge in demand for personalized medicine, which drives growth and innovation among companies like AbbVie and Novartis, who are focused on developing tailored therapeutic solutions. Furthermore, in September 2022, GSK confirmed their plans to invest in a new production facility in the GCC, reinforcing regional dedication to high-quality monoclonal antibody services amidst increasing health challenges. ## **GCC Monoclonal Antibody Custom Service Market Segmentation Insights** ### **Monoclonal Antibody Custom Service Market Type Outlook** - Rat Custom Monoclonal Antibody - Rabbit Custom Monoclonal Antibody ### **Monoclonal Antibody Custom Service Market Application Outlook** - Diagnostic Application (Biochemical Analysis (Pregnancy Cancer Hormonal Disorder And Infectious Diseases)) - Diagnostic Imaging (Cardiovascular Diseases, Cancer and Bacterial Infections) - Therapeutic Application (MAb as Therapeutic Agents and MAb as Targeting Agents) - Protein Purification ### **Monoclonal Antibody Custom Service Market End User Outlook** - Hospitals - Research ## Market Drivers ### Rising Prevalence of Chronic Diseases The increasing incidence of chronic diseases in the GCC region is significantly impacting the monoclonal antibody-custom-service market. Conditions such as cancer, diabetes, and autoimmune disorders are on the rise, necessitating advanced therapeutic solutions. According to recent health statistics, the prevalence of diabetes in the GCC is expected to reach 20% by 2030, highlighting the urgent need for effective treatments. Monoclonal antibodies have emerged as a promising option for managing these conditions, leading to heightened demand for custom services that can tailor these therapies to individual patient needs. This trend not only drives market growth but also encourages the development of specialized monoclonal antibody therapies, thereby enhancing the overall healthcare landscape in the region. ### Enhanced Regulatory Support for Biologics The regulatory landscape for biologics, including monoclonal antibodies, is evolving in the GCC region, providing a more supportive environment for the monoclonal antibody-custom-service market. Recent initiatives by regulatory authorities aim to streamline the approval processes for new therapies, thereby reducing time to market. In 2025, it is anticipated that the average approval time for monoclonal antibody therapies could decrease by 20% due to these regulatory enhancements. This improved regulatory framework not only encourages investment in the development of monoclonal antibodies but also instills confidence among stakeholders in the market. As a result, the monoclonal antibody-custom-service market is poised for growth, driven by a more efficient pathway for bringing innovative therapies to patients. ### Growing Focus on Research and Development The monoclonal antibody-custom-service market is witnessing a heightened emphasis on research and development (R&D) within the GCC region. Governments and private entities are increasingly recognizing the importance of R&D in driving innovation and improving healthcare outcomes. In 2025, R&D spending in the biopharmaceutical sector is projected to account for approximately 15% of total healthcare expenditure in the GCC. This focus on R&D is fostering collaborations between academic institutions and industry players, leading to the development of novel monoclonal antibody therapies. As a result, the monoclonal antibody-custom-service market is likely to benefit from a continuous influx of innovative solutions tailored to meet the evolving needs of patients and healthcare providers. ### Increasing Investment in Biopharmaceuticals The monoclonal antibody-custom-service market is experiencing a surge in investment from both public and private sectors in the GCC region. This influx of capital is primarily directed towards research and development of innovative biopharmaceuticals. In 2025, the biopharmaceutical sector in the GCC is projected to reach a valuation of approximately $10 billion, with monoclonal antibodies playing a pivotal role. The growing recognition of the therapeutic potential of monoclonal antibodies is driving this investment, as stakeholders seek to capitalize on their efficacy in treating various diseases. Furthermore, the establishment of specialized research facilities and partnerships with academic institutions enhances the capabilities of the monoclonal antibody-custom-service market, fostering an environment conducive to innovation and growth. ### Technological Advancements in Antibody Production Technological innovations in the production of monoclonal antibodies are transforming the monoclonal antibody-custom-service market. Advances in recombinant DNA technology and hybridoma techniques have streamlined the development process, reducing time and costs associated with antibody production. In 2025, it is estimated that the efficiency of monoclonal antibody production could improve by up to 30% due to these advancements. Additionally, the integration of automation and artificial intelligence in laboratory processes is enhancing the precision and scalability of antibody production. These technological improvements not only facilitate the rapid development of customized monoclonal antibodies but also attract investment and interest from pharmaceutical companies looking to optimize their therapeutic offerings. ## Future Outlook The [Monoclonal Antibody Custom Service Market](https://www.marketresearchfuture.com/reports/monoclonal-antibody-custom-service-market-4515) is projected to grow at a 5.14% CAGR from 2025 to 2035, driven by increasing demand for personalized medicine and advancements in biotechnological research. **New opportunities:** - Development of tailored monoclonal antibodies for niche therapeutic areas. - Expansion of contract manufacturing services to enhance production capacity. - Implementation of AI-driven analytics for optimized antibody design processes. By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships. ## Segment Insights ### By Type: Rat Custom Monoclonal Antibody (Largest) vs. Rabbit Custom Monoclonal Antibody (Fastest-Growing) In the GCC monoclonal antibody-custom-service market, Rat Custom Monoclonal Antibody holds a significant share, emerging as the largest segment due to its extensive use in research and diagnostics. This segment benefits from a strong demand in various therapeutic applications, contributing to its dominant market position. Meanwhile, Rabbit Custom Monoclonal Antibody, while smaller in market share, is rapidly gaining traction among researchers, particularly in immunology, signaling a shift in preference due to its unique advantages over other types. Growth trends indicate an increasing adoption of Rabbit Custom Monoclonal Antibodies, driven by advancements in antibody production technologies and a growing focus on personalized medicine. This segment is expected to witness rapid expansion as researchers seek higher specificity and sensitivity in their assays. The burgeoning biotech sector in the GCC is also fueling this growth, as demand for innovative research tools continues to rise, positioning Rabbit antibodies as key players in future developments. Rat Custom Monoclonal Antibody (Dominant) vs. Rabbit Custom Monoclonal Antibody (Emerging) Rat Custom Monoclonal Antibodies are highly regarded for their robust performance in various biological studies, resulting in strong demand from academic and pharmaceutical research institutions. Their established efficacy in generating high-quality antibodies has cemented their status as a dominant choice. Conversely, Rabbit Custom Monoclonal Antibodies are emerging as a competitive choice, especially in fields requiring higher specificity such as cancer research and autoimmune diseases. Their rapid growth is attributed to innovative developments in antibody engineering, with applications extending into diagnostics and targeted therapies. The versatility and adaptability of these antibodies make them increasingly popular in the market, highlighting the dynamic nature of research advancements in the GCC region. ### By Application: Therapeutic Application (Largest) vs. Diagnostic Imaging (Fastest-Growing) In the GCC monoclonal antibody-custom-service market, the distribution of market share among the application segments indicates a strong preference towards therapeutic applications, which hold the largest share due to their extensive use in treating chronic diseases. Diagnostic applications, while significant, have a smaller share, but still play a vital role in early disease detection and management. Protein purification is also critical, serving as a foundational element for various processes within these applications. The growth trends in the application segment are driven by advances in technology and an increasing prevalence of diseases requiring monoclonal antibody treatments. The therapeutic application segment is fueled by rising healthcare expenditures and a growing patient population. Conversely, the diagnostic imaging segment is emerging rapidly, primarily due to technological advancements and the need for faster, more accurate diagnostic tools that enhance patient care. Therapeutic Application: Dominant vs. Diagnostic Imaging: Emerging The therapeutic application segment remains the dominant force in the GCC monoclonal antibody-custom-service market, leveraging its extensive range of uses in treating numerous conditions, particularly in oncology and autoimmune disorders. This segment benefits from robust research initiatives and a clear focus on personalized medicine. On the other hand, the diagnostic imaging segment is characterized by swift innovation, with trends moving towards more integrated and efficient imaging techniques. The increasing demand for precise diagnostic tools positions this segment as an emerging player, driven by advancements in imaging technologies and the growing awareness of the importance of early diagnosis in improving health outcomes. ### By End User: Hospitals (Largest) vs. Research (Fastest-Growing) In the GCC monoclonal antibody-custom-service market, the predominant end user segment is hospitals, which command a significant share of the market. These establishments rely heavily on monoclonal antibodies for various therapeutic purposes, contributing to their dominance in the market. Research institutions represent a crucial segment as well, but they are currently experiencing rapid expansion which makes them an essential player in shaping the future of the market. The growth trends in the end user segment are driven by increased investment in healthcare infrastructure within the GCC region, particularly in hospitals where the demand for advanced therapies is rising. Research institutions are also expanding their capabilities, focusing on innovative applications of monoclonal antibodies. The rising prevalence of chronic diseases and increased funding for research initiatives are facilitating this growth, positioning both hospitals and research institutions as key stakeholders in the ongoing development of monoclonal antibody therapies. End Users: Hospitals (Dominant) vs. Research (Emerging) Hospitals play a dominant role in the GCC monoclonal antibody-custom-service market due to their extensive utilization of these therapies for patient care. They are equipped to conduct large-scale treatments, and their established infrastructure allows for efficient delivery of monoclonal antibody therapies. Conversely, research institutions are emerging as vital contributors to the market, leveraging advances in scientific research to explore new therapeutic applications. Their agility and focus on innovation enable them to adapt quickly to market trends, thus position them as a rapidly growing segment. The collaboration between hospitals and research institutions further enhances the development and application of monoclonal antibodies, combining clinical needs with research advancements. ## Competitive Benchmarking The monoclonal antibody-custom-service market is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in biopharmaceuticals. Key players such as Thermo Fisher Scientific (US), Roche (CH), and AbbVie (US) are strategically positioned to leverage their extensive portfolios and technological capabilities. Thermo Fisher Scientific (US) focuses on innovation through continuous investment in R&D, enhancing its service offerings to meet the evolving needs of clients. Roche (CH) emphasizes partnerships with academic institutions to foster innovation, while AbbVie (US) is actively pursuing mergers and acquisitions to expand its capabilities and market reach. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of services and solutions, catering to various client needs while fostering competition among established and emerging players. In October Roche (CH) announced a strategic partnership with a leading biotechnology firm to co-develop novel monoclonal antibodies targeting rare diseases. This collaboration is expected to enhance Roche's pipeline and strengthen its position in niche markets, reflecting a broader trend of companies seeking to innovate through strategic alliances. The partnership underscores the importance of collaboration in accelerating the development of cutting-edge therapies. In September AbbVie (US) completed the acquisition of a biotech startup specializing in antibody-drug conjugates. This acquisition is likely to bolster AbbVie's capabilities in targeted therapies, aligning with its strategic focus on expanding its oncology portfolio. The move illustrates a trend where established companies are acquiring innovative firms to enhance their technological edge and product offerings. In August Thermo Fisher Scientific (US) launched a new platform for monoclonal antibody production that integrates AI-driven analytics to optimize yield and quality. This initiative not only demonstrates Thermo Fisher's commitment to digital transformation but also highlights the growing importance of technology in enhancing operational efficiency and product quality in the market. As of November current competitive trends indicate a strong emphasis on digitalization, sustainability, and AI integration within the monoclonal antibody-custom-service market. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability, as companies strive to meet the complex demands of the biopharmaceutical industry. ## Recent News & Developments The GCC Monoclonal Antibody Custom Service Market has seen significant developments, particularly with major companies like Siemens Healthineers, Amgen, Bristol-Myers Squibb, Pfizer, Merck, and Regeneron Pharmaceuticals actively expanding their footprints in the region. In August 2023, Roche entered into a strategic partnership with a local biotech firm to enhance the development of monoclonal antibody therapies, responding to the growing demand for customized solutions. In December 2022, Johnson and Johnson expanded their facilities in the GCC to facilitate better production and research capabilities aimed at monoclonal antibody innovation. Significant increases in market valuation have been noted across the sector, with Thermo Fisher Scientific and Eli Lilly reporting growth attributed to enhanced investments in Research and Development and local collaborations. The last couple of years has seen a surge in demand for personalized medicine, which drives growth and innovation among companies like AbbVie and Novartis, who are focused on developing tailored therapeutic solutions. Furthermore, in September 2022, GSK confirmed their plans to invest in a new production facility in the GCC, reinforcing regional dedication to high-quality monoclonal antibody services amidst increasing health challenges. ## Report Scope | MARKET SIZE 2024 | 20.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 21.55(USD Million) | | MARKET SIZE 2035 | 35.58(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.14% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Roche (CH), AbbVie (US), Merck KGaA (DE), Amgen (US), Sartorius (DE), GenScript (CN), Lonza (CH), Boehringer Ingelheim (DE) | | Segments Covered | Type, Application, End User | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in the monoclonal antibody-custom-service market. | | Key Market Dynamics | Rising demand for personalized medicine drives growth in monoclonal antibody-custom-service offerings across the region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What was the market valuation of the GCC monoclonal antibody-custom-service market in 2024?** A: The market valuation was $20.5 Million in 2024. **Q: What is the projected market valuation for the GCC monoclonal antibody-custom-service market in 2035?** A: The projected valuation for 2035 is $35.58 Million. **Q: What is the expected CAGR for the GCC monoclonal antibody-custom-service market during the forecast period 2025 - 2035?** A: The expected CAGR is 5.14% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the GCC monoclonal antibody-custom-service market?** A: Key players include Thermo Fisher Scientific, Roche, AbbVie, Merck KGaA, Amgen, Sartorius, GenScript, Lonza, and Boehringer Ingelheim. **Q: What are the main types of custom monoclonal antibodies offered in the market?** A: The main types include Rat Custom Monoclonal Antibody and Rabbit Custom Monoclonal Antibody. **Q: What was the market value for Rat Custom Monoclonal Antibody in 2024?** A: The market value for Rat Custom Monoclonal Antibody was $8.2 Million in 2024. **Q: What is the projected market value for Rabbit Custom Monoclonal Antibody in 2035?** A: The projected market value for Rabbit Custom Monoclonal Antibody in 2035 is $21.48 Million. **Q: What applications are driving the demand for monoclonal antibody-custom services?** A: Demand is driven by applications such as Diagnostic Application, Diagnostic Imaging, Therapeutic Application, and Protein Purification. **Q: What was the market value for Therapeutic Application in 2024?** A: The market value for Therapeutic Application was $8.0 Million in 2024. **Q: Which end users are primarily utilizing monoclonal antibody-custom services?** A: Primary end users include Hospitals and Research institutions, each valued at $10.25 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-monoclonal-antibody-custom-service-market-52991*